Working… Menu

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02531516
Recruitment Status : Active, not recruiting
First Posted : August 24, 2015
Last Update Posted : December 3, 2021
Information provided by (Responsible Party):
Aragon Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : October 6, 2026